GlassScriptPhysician profile
Blaine R Oswald
NPI 1285235341
$19,268.40
in general payments reported to CMS, 2019-2025
20 companies · $4,715 in 2025
The $4,715 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,126 · 2022: $3,892 · 2023: $4,635 · 2024: $4,901 · 2025: $4,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,891 · Food and Beverage: $3,316 · Consulting Fee: $1,275 · Travel and Lodging: $658 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,891.00 |
| Food and Beverage | $3,315.52 |
| Consulting Fee | $1,275.00 |
| Travel and Lodging | $658.03 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $10,596.85 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $3,629.42 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,230.43 | 2022-2024 | Rejoyn, Abilify Asimtufii |
| Alkermes, INC. | $867.22 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $851.77 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $576.95 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $282.27 | 2021-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $273.96 | 2021-2025 | Invega Sustenna, Spravato |
| E.R. Squibb & Sons, L.L.C. | $195.18 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.52 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $105.62 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $101.66 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $95.06 | 2023-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $52.07 | 2022-2024 | Qelbree, Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.69 | 2021-2025 | Trintellix |
| Almatica Pharma LLC | $33.97 | 2024-2025 | Loreev Xr |
| Indivior INC. | $32.87 | 2021-2022 | |
| Eisai INC. | $29.22 | 2021 | |
| Tris Pharma INC | $14.67 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blaine Oswald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.